RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

Dew, good point on cost-shifting to the biotech investors. How many times though, can you sell the Brooklyn Bridge? Not likely to Cor shareholders.

Haysaw, last time I looked, the government investment into diabetes R+D was < 1% of what was they paid in patient care in that area. This is also the disease, with fastest world wide growth, that will break the health care budgets.

Pressures to reduce patent life and the increased safety expectations and requirements of new drugs will further conspire to reduce likelihood of biotech profitability. A lot more than good management is required. In health care delivery it will be easy to provide good management, but no one will like it. It will equate to rationing in a disguised form.

I liked the story of the ABT secretary who bought 3 shares of ABT for 180 in 1935, reinvested dividend and cashed out 7 million (annualized 15%). Will this happen again in pharma?